Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, announced today that data from two significant phase III clinical trials using its ...

This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.

Clinical characteristics and long-term outcomes of extreme responders to first line treatment of metastatic prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers ...

Please provide your email address to receive an email when new articles are posted on . Use of a precision navigator led to significant increase in genomic profiling among men with prostate cancer.

(NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-analysis of Prolaris to date, ...

A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...

For many men, a prostate cancer scare starts with one number. A PSA result comes back high, and ...

A next-generation Stockholm3 blood test detected aggressive prostate cancer more accurately than PSA, improving early ...

Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care The OPTIMA study is a prospective, ...